Targeting a specific protein to treat eye pressure and glaucoma
Selective Inhibition of GRP 94 to Treat Ocular Hypertension and Glaucoma
['FUNDING_R01'] · UNIVERSITY OF NOTRE DAME · NIH-10859324
This study is looking at how a protein called Grp94 affects eye pressure and glaucoma, and it aims to find new treatments that could help people with these conditions by reducing harmful protein buildup in the eye.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NOTRE DAME (nih funded) |
| Locations | 1 site (NOTRE DAME, UNITED STATES) |
| Trial ID | NIH-10859324 on ClinicalTrials.gov |
What this research studies
This research investigates the role of a protein called Grp94 in the development of ocular hypertension and glaucoma, conditions that can lead to vision loss. The study focuses on how mutant myocillin, a protein associated with these eye conditions, causes cellular stress and dysfunction. By using selective inhibitors of Grp94, the researchers aim to reduce the harmful aggregation of proteins and restore normal eye pressure. Patients may benefit from new topical treatments developed through this research that could improve their eye health.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with primary open-angle glaucoma (POAG) or those experiencing steroid-induced glaucoma.
Not a fit: Patients with other forms of glaucoma not related to the mechanisms being studied may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments for managing ocular hypertension and glaucoma, potentially preserving vision for many patients.
How similar studies have performed: Previous studies have shown promise in targeting similar pathways for treating glaucoma, indicating a potential for success with this approach.
Where this research is happening
NOTRE DAME, UNITED STATES
- UNIVERSITY OF NOTRE DAME — NOTRE DAME, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: BLAGG, BRIAN S J — UNIVERSITY OF NOTRE DAME
- Study coordinator: BLAGG, BRIAN S J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Alzheimer disease dementia, Alzheimer syndrome, Alzheimer's Disease